Outcomes of elective cancer surgery during the COVID-19 pandemic crisis: an international, multicentre, observational cohort study (CovidSurg-Cancer)

The rapid emergence of the COVID-19 virus has led to a global impact on elective surgical care. We have very little evidence to guide us. The magnitude and effects of these changes are uncertain. The safety of operating on patients electively with the risks of COVID-19 postoperative pneumonia is unknown. High-quality data will allow policy planning at regional and hospital level for both this outbreak and future pandemics. CovidSurg-Cancer will run in parallel to CovidSurg (which is capturing outcomes of patients undergoing surgery for all indications with concurrent COVID-19).

In order to contribute to CovidSurg-Cancer you must first secure appropriate approvals and senior surgeon leadership, according to local regulations. This short protocol has been written to support that process. This investigator-led, non-commercial, non-interventional study is extremely low to zero risk. This study does not collect any patient identifiable information and data will not be analysed at hospital-level.

Any centre that performs elective cancer surgery and has been affected by COVID-19 is eligible for participation. Investigators may choose one or more cancer types from their centre from which to upload data. This study be performed prospectively, retrospectively or using a mixed model, dependent on the phase of COVID-19 infection in your hospital.

Mr Aneel Bhangu, MBChB PhD FRCS Consultant Surgeon, University Hospital Birmingham, UK

CovidSurg-Cancer

Study Protocol V6.0

Primary aim

• To evaluate the 30-day postoperative pulmonary complication rate following elective cancer¹ surgery during the COVID-19 pandemic.

Secondary aims

- To evaluate the 30-day SARS-CoV-2 infection rate following elective cancer¹ surgery.
- To compare the 30-day postoperative mortality rate in cancer surgery patients that develop COVID-19 infection versus those who do not.
- To explore the scale of resource constraints related to the COVID-19 pandemic, and their impact on outcomes of elective cancer surgery of curative intent^{2,3}.
- To explore variation in the selection of patients for continuing elective cancer surgery during the COVID-19 pandemic.
- To evaluate the impact of the COVID-19 pandemic on treatment pathways for cancers with a decision for surgical resection with curative intent up to 6-months after their initial treatment decision.

¹Any intracranial tumour (benign or malignant) may be included for neurosurgical patients. This applies throughout the protocol when reference is made to 'cancer'.

²Curative intent is not required for the inclusion of patients with intracranial tumours. This applies throughout the remainder of the protocol when reference is made to 'curative intent'.

³In gynaecological oncology, a plan for surgery with curative intent or life-prolonging intent are both eligible.

Inclusion criteria

Any centres performing elective cancer surgery¹ are eligible for participation. Centres will be stratified according to their national burden of COVID-19 infections using data from the World Health Organisation, and their COVID-19 status (designated COVID-19 free 'cold', COVID-19 affected 'hot' surgical units, or undesignated units with or without an emergency department co-located).

CovidSurg-Cancer study will capture:

- Patients with a multidisciplinary team (tumour board) decision for curative cancer surgery^{2,3} that have surgery completed during the COVID-19 pandemic.
- Patients that <u>would have been planned</u> for curative cancer surgery by the MDT (tumour board) in the <u>pre-COVID-19 era</u> that have surgery delayed, cancelled, or receive an alternative treatment strategy (e.g. radiotherapy) during the pandemic.

Patient inclusion criteria:

- Adults (age \geq 18 years) with a confirmed diagnosis of an included cancer type¹.
- Multidisciplinary team (tumour board) decision for (or **would have been made** for) surgical management with a curative intent during the pre-COVID-19 era^{2,3}.

Patient exclusion criteria:

- Surgery planned with non-curative intent.
- Planned chemo- or radiotherapy without a firm date for surgery, or awaiting restaging.

Patient enrolment

Centres can elect to include <u>one or more</u> cancer types in the study, in any combination, depending on local expertise and capacity. Investigators can enrol patients with confirmed diagnoses of Colorectal, Oesophagogastric, Head & Neck, Lung, Hepatopancreatobilary, Urological, Gynaecological, Breast cancers, soft-tissue or bone Sarcoma, and Intracranial tumours (both benign and malignant). As a rapid response study to the COVID-19 pandemic, included cancer types have evolved following a short pilot period.

Study period

Investigators should identify a start date, which represents the start of the emergence of COVID-19 in their hospital (or city/area if designated COVID-free hospital). At that stage, they should capture all patients who have had a decision for surgery at this time point, and then all patients with a new diagnosis and with a decision to surgery for the next 3 months (representing the peak period of the COVID-19 pandemic). We envisage most sites completing registration before August 2020 and completing follow-up by December 2020. However, changes to dates may be necessary as the disease changes, and we may develop a third phase for longer follow-up in selected sites with the capacity to do so.




Figure 1. Timeline for patient identification within CovidSurg-Cancer

Primary outcome measure

• 30-day postoperative pulmonary complication rate.

Secondary outcome measures

- 30-day postoperative SARS-CoV-2 infection rate.
- 30-day postoperative mortality rate.
- Postoperative critical care utilisation rate in high-risk cancer surgery patients.
- Proportion of patients with delay of greater than 4 weeks from decision for surgery to date of surgery.
- Proportion of non-operated patients with progression to incurable disease by 3-months and 6-months after decision for surgery.

Follow-up period

- Outcomes for **operated patients** will be collected up to **30-days** postoperatively (with Day 0 as the day of surgery).
- Outcomes for **non-operated patients** should be collected up to **3-months** and **6-months** from their study entry.




Figure 2. Timing of outcome assessment in CovidSurg-Cancer

Data collection

Data will be collected and stored online through a secure server running the Research Electronic Data Capture (REDCap) web application. REDCap allows collaborators to enter and store data in a secure, encrypted system. A designated collaborator at each participating site will be provided with REDCap project server login details, allowing them to securely submit data on to the REDCap system. REDCap has previously been successfully used for a range of other international cohort studies led by the central unit, including the GlobalSurg (www.globalsurg.org) and European Society of Coloproctology Audits and Cohort studies (https://www.escp.eu.com/research/cohort-studies). The REDCap server is managed by the University of Birmingham, UK. Only anonymised data will be uploaded to the database. No patient identifiable data, and no specific dates will be collected.

Data collected will include baseline demographic data, cancer-specific data, timelines for dates of diagnosis, decision for surgery and operation or completion of follow-up (summarised at a week level), operative and nonoperative cancer-related treatment, treatment related to COVID-19 (where applicable), pathology and clinical outcome data. Restricted additional cancer group-specific data will be collected to support individual cancer-level analyses. Data can be collected prospectively, or retrospectively where required, depending on the COVID-19 status of your hospital. A centre-level survey will collect data on departmental decision making processes, and the impact of COVID-19 on elective surgical services in each included hospital.

Roles within the data collection team

The principal investigator at each site should identify a team to:

- Identify patients waiting for curative surgery at the estimated start date.
- Proactively identify patients with a new decision for (or would have had a decision made for curative surgery in the pre-COVID-19 era) during the study window.
- Monitor this patient cohort at regular intervals (e.g. weekly) to check their status up to completion of follow-up.
- Acquire outcome data at 30 days postoperatively for operated patients, and at 3- and 6months from study entry for non-operated patients.

No limits to the size of this team are imposed, and can be flexible to local capacity and service demands.

Local approvals

The principal investigator at each participating site is responsible for obtaining necessary local approvals (e.g. service evaluation, audit approval, research ethics committee or institutional review board approval). Local approvals should cover inclusion of all cancer types within this study. Collaborators will be required to confirm that relevant local approval is in place at the time of uploading each patient record to the study database. The study will be carried out in accordance with national and international guidelines, as well as the basic principles of the protection of the rights and dignity of Human Beings, as set out in the Helsinki Declaration (64th Assembly Fortaleza, Brazil, in October 2013), and according to current legislation.

Where an audit approval is needed, this can be either registered as service evaluation, or to benchmark against an auditable standard. For example, NHS Delivering Cancer Waiting Times - Good Clinical Practice Guide (2014):

• A maximum of one month wait from the date between a decision to treat (DTT) to the first definitive treatment for all cancers (including surgery).

Available at: www.england.nhs.uk/wp-content/uploads/2015/03/delivering-cancer-wait-times.pdf

Prior to formal local study approval, collaborators may prospectively collect data on hard copy case report forms (available at <u>https://globalsurg.org/cancercovidsurg/</u>), but this should not be uploaded to the REDCap database until approval is confirmed.

Analysis

A detailed statistical analysis plan will be published online at <u>globalsurg.org/cancercovidsurg</u>. Analyses will be overseen by the independent data monitoring committee (DMC). Reports will include description of the primary and secondary outcomes in the cohort. Interim analyses will be performed as guided by the independent DMC, and rapidly disseminated to the global healthcare community using social media, blog sites and health education platforms. The first analysis will be performed once 100 patients have been entered onto the database, and the frequency of subsequent analyses will be agreed with the DMC. The decision to submit data for publication will be agreed by the CovidSurg-Cancer steering committee upon consultation with the DMC. Hospital-level data will not be released or published.

Authorship

All collaborators from sites who contribute at least one patient will be recognised on any resulting publications as PubMed-citable co-authors. Flexible to service demands, no authorship limits will be imposed at a centre level; as many collaborating investigators are required, and work to support the project will be recognised on all future outputs.

A corporate authorship model will be used under CovidSurg Collaborative group, for example: <u>https://pubmed.ncbi.nlm.nih.gov/29452941</u>.




Figure 3. Overview of patient and pathways captured within CovidSurg-Cancer protocol.

CovidSurg-Cancer: Operations Group

James C Glasbey (CovidSurg-Cancer lead), Dmitri Nepogodiev (CovidSurg lead), Kwabena Siaw-Acheampong, Daoud Chaudhry, Brett E Dawson, Jonathan P Evans, Rohan R Gujjuri, Emily Heritage, Conor S Jones, Sivesh K Kamarajah, Chetan Khatri, James M Keatley, Samuel Lawday, Elizabeth Li, Siobhan C Mckay, Gianluca Pellino, Abhinav Tiwari, Joana FF Simoes, Isobel M Trout, Mary L Venn, Richard JW Wilkin, Aneel Bhangu (Overall guarantor).

CovidSurg-Cancer: Dissemination Committee

Michel Adamina, Adesoji O Ademuyiwa, Arnav Agarwal, Ehab Alameer, Derek Alderson, Felix Alakaloko, Osaid Alser, Alexis P Arnaud, Knut Magne Augestad, Brittany K Bankhead-Kendall, Emma Barlow, Ruth A Benson, Ruth Blanco-Colino, Amanpreet Brar, Ana MinayaBravo, Kerry A Breen, Igor Lima Buarque, Edward J Caruana, Sohini Chakrabortee, Daniel Cox, Miguel F Cunha, Giana H Davidson, Anant Desai, Salomone Di Saverio, Thomas D Drake, John G Edwards, Muhammed Elhadi, Shebani Farik, Marco Fiore, J Edward Fitzgerald, Samuel Ford, Gaetano Gallo, Dhruv Ghosh, Gustavo Mendonça Ataíde Gomes, Ewen A Griffiths, Constantine Halkias, Ewen M Harrison, Peter J Hutchinson, Arda Isik, Michael D Jenkinson, Haytham MA Kaafarani, Angelos Kolias, Ismail Lawani, Hans Lederhuber, Sezai Leventoglu, Markus W Löffler, Janet Martin, Hassan N Mashbari, Dennis Mazingi, Symeon Metallidis, Ana Minaya-Bravo, Helen M Mohan, Rachel Moore, David Moszkowicz, Susan Moug, Joshua S Ng-Kamstra, Milagros Niquen, Faustin Ntirenganya, Oumaima Outani, Francesco Pata, Thomas D Pinkney, Peter Pockney, Dejan Radenkovic, Antonio Ramos-De la Medina, Keith Roberts, April C Roslani, Irene Santos, Andrew Schache, Andreas A Schnitzbauer, Grant D Stewart, Richard Shaw, Sebastian Shu, Kjetil Soreide, Antonino Spinelli, Sudha Sundar, Stephen Tabiri, Philip Townend, Georgios Tsoulfas, Gabrielle H van Ramshorst, Raghavan Vidya, Dale Vimalachandran, Oliver J Warren, Naomi Wright, EuroSurg, European Society of Coloproctology (ESCP), GlobalSurg, GlobalPaedSurg, ItSURG, PTSurg, SpainSurg, Italian Society of Colorectal Surgery (SICCR), Association of Surgeons in Training (ASiT), Irish Surgical Research Collaborative (ISRC), Joana FF Simoes (Chair).

Specialty group	Name	Country	Email
Colorectal	Neil Smart*	UK	drneilsmart@hotmail.com
	Ana Minaya-Bravo	Spain	ana-minaya@hotmail.com
	Jon Evans	UK	drjpevans@doctors.org.uk
	Susan Moug	UK	susanmoug@nhs.net
	Dale Vimalchandran	UK	dale.vimalachandran@nhs.net
	Abi Vallance	UK	a.e.vallance@gmail.com
	Peter Pockney	Australia	peter.pockney@newcastle.edu.au
Oesophagogastric	Ewen Griffiths*	UK	Ewen.Griffiths@uhb.nhs.uk
	Sivesh Kamarajah	UK	siveshkk93@gmail.com
	Richard Evans	UK	rptevans@doctors.org.uk
	Philip Townend	Australia	Philip.Townend@health.qld.gov.au
Hepatopancreatobilary	Siobhan McKay*	UK	mckay.siobhan@gmail.com
	Keith Roberts*	UK	Keith.Roberts@uhb.nhs.uk
	John Isaac	UK	John.Isaac2@uhb.nhs.uk
	Sohei Satoi	Japan	satoi@hirakata.kmu.ac.jp

CovidSurg-Cancer: Specialty Leads

*First point of contact

	John Edwards*	UK	john.edwards3@nhs.net
	Aman Coonar	UK	aman.coonar@nhs.net
	Adrian Marchbank	UK	adrian.marchbank@nhs.net
Thoracics	Edward Caruana	UK	edwardcaruana@nhs.net
		UK	g.layton@nhs.net
	Georgia Layton		
	Akshay Patel	UK	a.patel.2@bham.ac.uk
Sarcoma	Samuel Ford*	UK	samuel.ford@uhb.nhs.uk
	Anant Desai*	UK	anant.desai@uhb.nhs.uk
	Max Almond	UK	max.almond@uhb.nhs.uk
	Fabio Tirotta	Italy	fabio.tirotta.chirurgia@gmail.com
	Marco Fiore	Italy	Marco.Fiore@istitutotumori.mi.it
	Sinziana Dumitra	Canada	sinziana.dumitra@gmail.com
	Angelos Kolias*	UK	angeloskolias@gmail.com
	Stephen Price	UK	sjp58@cam.ac.uk
	Daniel Fountain	UK	daniel.fountain@nhs.net
	Michael Jenkinson	UK	michael.jenkinson@liverpool.ac.uk
	Peter Hutchinson	UK	pjah2@cam.ac.uk
	Hani Marcus	UK	h.marcus@ucl.ac.uk
	Rory Piper	UK	rorypiper@doctors.org.uk
	Laura Lippa,	Italy	laura.lippa@gmail.com
Neurosurgery	Franco Servadei	Italy	franco.servadei@gmail.com
0,1	Ignatius Esene	Cameroon	ignatiusesene@yahoo.co.uk
	Christian Freyschlag	Austria	christian.freyschlag@tirol-kliniken.at
	luri Neville	Brazil	iuri.neville@hc.fm.usp.br
	Gail Rosseau	USA	gailrosseaumd@gmail.com
	Karl Schaller	Switzerland	karl.schaller@hcuge.ch
	Andreas Demetriades	UK	andreas.demetriades@gmail.com
	Faith Robertson	USA	faithrobertson13@gmail.com
	Alex Alamri	UK	alex.alamri@gmail.com
	Richard Shaw*	UK	richard.shaw@liverpool.ac.uk
	Andrew Schache	UK	andrew.schache@liverpool.ac.uk
	Stuart Winter	UK	stuart.winter@nds.ox.ac.uk
	Michael Ho	UK	michael.ho2@nhs.net
Head and neck	Paul Nankivell	UK	p.c.nankivell@bham.ac.uk
	Juan Rey Biel	Spain	jreybiel@gmail.com
	Martin Batstone	Australia	martin.batstone@health.qld.gov.au
	lan Ganly	USA	anlyi@mskcc.org
	Vidya Raghavan*	UK	raghavan.vidya@nhs.net
Broast surgery	Alex Wilkins	UK	alewilkins@gmail.com
Breast surgery	Japdeep Singn	UK	jkrai@hotmail.com
			JKrai@notmail.com
	Sudha Sundar*	UK	_
	Christina Fotopoulou*	UK	_
	Elaine Leung	UK	_
	Tabassum Khan	UK	_
	Luis Chiva	Spain	_
Gynaecological	Jalid Sehouli	Germany	
oncology	Anna Fagotti	Italy	gocovidsurg@gmail.com
oncology	Paul Cohen	Australia	_
	Murat Gutelkin	Turkey	
	Rahel Ghebre	Ethiopia	
	Thomas Konney	Ghana	
	Rene Pareja	Columbia	
1	Rob Bristow	USA	

	Sean Dowdy	USA	
	Shylasree	India	
	TS Rajkumar	India	
	Joe Ng	Singapore	
	Keiiji Fujiwara	Japan	
Urology	Grant Stewart*	UK	gds35@cam.ac.uk
	Benjamin Lamb	UK	
	Krishna Narahari	UK	krishna.narahari@wales.nhs.uk
	Alan McNeill	UK	Alan.McNeill@nhslothian.scot.nhs.uk
	Alexandra Colquhoun	UK	alexandra.colquhoun@addenbrookes.nhs.uk
	John McGrath	UK	john.mcgrath4@nhs.net
	Steve Bromage	UK	steve.bromage@nhs.net
	Ravi Barod	UK	ravibarod@gmail.com
	Veeru Kasivisvanathan	UK	veeru.kasi@ucl.ac.uk